

Uwe K Zettl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5433792/publications.pdf>

Version: 2024-02-01

77
papers

2,503
citations

236925

25
h-index

223800

46
g-index

77
all docs

77
docs citations

77
times ranked

4066
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. <i>Brain</i> , 2023, 146, 977-990.	7.6	10
2	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 865-871.	3.0	8
3	Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Current Pharmaceutical Design</i> , 2022, 28, 428-436.	1.9	10
4	Epilepsy as a predictor of disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 942-949.	3.0	12
5	Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. <i>Neurological Sciences</i> , 2022, 43, 2631-2639.	1.9	3
6	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17
7	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.1	14
8	Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103534.	2.0	7
9	Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS. <i>Current Pharmaceutical Design</i> , 2022, 28, 427-427.	1.9	1
10	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	10.1	27
11	Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT. <i>Advances in Therapy</i> , 2022, 39, 2749-2760.	2.9	6
12	Current Pharmaceutical Trends in Neuroimmunology - Part II: Autoimmunity Beyond the CNS and Other Disorders. <i>Current Pharmaceutical Design</i> , 2022, 28, 853-853.	1.9	1
13	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	11
14	Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110225.	3.5	1
15	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1033-1043.	1.9	26
16	Headache in multiple sclerosis - pharmacological aspects. <i>Current Pharmaceutical Design</i> , 2021, 27, .	1.9	2
17	Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103281.	2.0	6
18	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38

#	ARTICLE	IF	CITATIONS
19	Management of MS Patients Treated With Daclizumab â€“ a Case Series of 267 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 996.	2.4	8
20	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102485.	2.0	26
21	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	6.0	7
22	Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020, 143, e97-e97.	7.6	8
23	Tick-borne encephalitis vaccination in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	12
24	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	1.9	66
25	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
26	Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100574.	1.1	5
27	Is APOE Î¼4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	6.0	11
28	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. <i>EBioMedicine</i> , 2020, 56, 102822.	6.1	17
29	Editorial: Multiple Sclerosis â€“ From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients. <i>Frontiers in Immunology</i> , 2020, 11, 137.	4.8	4
30	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	4.1	1
31	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	4.2	29
32	Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 286-294.	3.6	23
33	Vaccination in Multiple Sclerosis: Friend or Foe?. <i>Frontiers in Immunology</i> , 2019, 10, 1883.	4.8	70
34	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	9.0	48
35	A smart peek: Processing of rapid visual displays is disturbed in newly diagnosed, cognitively intact MS patients and refers to cognitive performance and disease progression in late stages. <i>Journal of the Neurological Sciences</i> , 2019, 401, 118-124.	0.6	1
36	Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases. <i>Journal of Immunology</i> , 2019, 202, 2177-2187.	0.8	53

#	ARTICLE	IF	CITATIONS
37	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.6	24
38	Headache in the course of multiple sclerosis: a prospective study. <i>Journal of Neural Transmission</i> , 2019, 126, 131-139.	2.8	11
39	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	3.0	12
40	Coping behavior in multiple sclerosisâ€”complementary and alternative medicine: A crossâ€”sectional study. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 784-789.	3.9	16
41	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	7.6	115
42	Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosineâ€”phosphate receptor modulator. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 193-201.	3.9	32
43	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e446.	6.0	54
44	Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 483-498.	1.8	71
45	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	3.0	11
46	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
47	Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study. <i>European Neurology</i> , 2018, 80, 115-120.	1.4	13
48	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 497-498.	10.2	10
49	Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 173-174.	2.0	7
50	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
51	Information processing deficits as a driving force for memory impairment in MS: A crossâ€”sectional study of memory functions and MRI in early and late stage MS. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 119-127.	2.0	8
52	Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. <i>Autoimmunity Reviews</i> , 2017, 16, 925-936.	5.8	68
53	Hans Queckenstedt (1876â€”1918). <i>Journal of Neurology</i> , 2017, 264, 1032-1034.	3.6	1
54	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , 2017, 31, 33-50.	5.9	57

#	ARTICLE	IF	CITATIONS
55	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	1.8	13
56	Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1888-1890.	3.0	28
57	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€œAustrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	3.6	46
58	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.3	133
59	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsingâ€œremitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	3.0	40
60	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016, 12, 217-233.	10.1	199
61	Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 9-30.	3.5	51
62	Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. <i>Autoimmunity Reviews</i> , 2016, 15, 210-220.	5.8	105
63	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	1.3	15
64	Cell-specific effects in different immune subsets associated with <i>SOCS1</i> genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1498-1512.	3.0	8
65	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	7.6	93
66	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015, 278, 277-279.	2.3	15
67	Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis â€œ an observational study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 587-593.	3.4	17
68	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	3.2	34
69	Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. <i>PLoS ONE</i> , 2015, 10, e0134583.	2.5	41
70	Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics. <i>Journal of Neuroimmunology</i> , 2014, 277, 145-152.	2.3	5
71	Progressive multifocal leukoencephalopathy in a patient with pre-clinical primary biliary cirrhosis. <i>Clinical Neurology and Neurosurgery</i> , 2014, 123, 45-49.	1.4	6
72	Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). <i>European Journal of Health Economics</i> , 2014, 15, 953-966.	2.8	24

#	ARTICLE	IF	CITATIONS
73	Immune-mediated CNS diseases: A review on nosological classification and clinical features. Autoimmunity Reviews, 2012, 11, 167-173.	5.8	93
74	Pioneers in neurology: Johannes Sayk (1923â€“2005). Journal of Neurology, 2009, 256, 2109-2110.	3.6	3
75	Oxides and apoptosis in inflammatory myopathies. Microscopy Research and Technique, 2001, 55, 249-258.	2.2	14
76	Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?. Movement Disorders, 2000, 15, 1279-1281.	3.9	14
77	Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. , 1999, 28, 34-39.		44